Crystal structure of an L chain optimised 14F7 anti-ganglioside Fv suggests a unique tumour-specificity through an unusual H-chain CDR3 architecture

Targeted cancer immunotherapy offers increased efficacy concomitantly with reduced side effects. One antibody with promising clinical potential is 14F7, which specifically recognises the NeuGc GM3 ganglioside. This antigen is found in the plasma membrane of a range of tumours, but is essentially abs...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjerregaard-Andersen, Kaare, Johannesen, Hedda, Abdel-Rahman, Noha, Heggelund, Julie Elisabeth, Hoås, Helene Mykland, Abraha, Fana, Bousquet, Paula A., Høydahl, Lene Støkken, Burschowsky, Daniel, Rojas, Gertrudis, Oscarson, Stefan, Løset, Geir Åge, Krengel, Ute
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052152/
https://www.ncbi.nlm.nih.gov/pubmed/30022069
http://dx.doi.org/10.1038/s41598-018-28918-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052152/
https://www.ncbi.nlm.nih.gov/pubmed/30022069
http://dx.doi.org/10.1038/s41598-018-28918-5

Ejemplares similares